Stay updated with breaking news from Exhalation Delivery System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis in two randomized controlled Phase 3 Clinical Trials FDA Supplemental New Drug Application...
/cloudfront-us-east-1.images.arcpublishing.com/gray/C5PIWTBB2JBRBF6N4WEC7CFWO4.jpg)
There’s a new device designed to help patients who have sinusitis and nasal polyps.
06.09.2022 - ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical RhinologyYARDLEY, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) - Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and ... Seite 1
Penny stocks are priced under $5 and often represent high-risk public companies that do offer exponential growth potential.
Positive topline results were announced from a phase 3 trial evaluating intranasal admin of OPN-375 in patients with chronic sinusitis.